Hainan Zanbond Pharmaceutical

Hainan Zanbond Pharmaceutical is a specialized pharmaceutical company based in China, primarily focused on the respiratory and anti-infective therapeutic areas. Formerly a subsidiary of the Italian Zambon Group, the company was acquired by Grandpharma in 2021 to bolster its respiratory product line. The company is well-known for its flagship products, including the mucolytic agent Fluimucil (acetylcysteine) and the antibiotic Monurol (fosfomycin). Zanbond operates a large-scale, GMP-certified manufacturing facility in the Haikou National High-tech Zone, producing various dosage forms such as granules, tablets, and inhalants. As a key member of the Grandpharma group, it continues to integrate research, production, and sales to serve the Chinese healthcare market.